aTyr Pharma (NASDAQ:ATYR) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of aTyr Pharma (NASDAQ:ATYR) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $25.67.

aTyr Pharma Price Performance

Shares of ATYR stock opened at $0.95 on Friday. The company has a market capitalization of $92.78 million, a P/E ratio of -1.20 and a beta of 0.66. The company’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $0.82. aTyr Pharma has a one year low of $0.64 and a one year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last issued its earnings results on Thursday, March 5th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. On average, research analysts expect that aTyr Pharma will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Profund Advisors LLC bought a new position in aTyr Pharma during the 3rd quarter worth about $27,000. California State Teachers Retirement System bought a new position in aTyr Pharma during the 2nd quarter worth about $28,000. ADAR1 Capital Management LLC grew its holdings in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new position in aTyr Pharma during the 4th quarter worth about $41,000. Finally, Legal & General Group Plc bought a new position in aTyr Pharma during the 2nd quarter worth about $49,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.